{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T06:39:16Z","timestamp":1777703956983,"version":"3.51.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s00520-023-08021-w","type":"journal-article","created":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T02:02:15Z","timestamp":1693533735000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Prevalence and clinical outcomes of vitamin D deficiency among Japanese multiple myeloma patients: a single-center observational study"],"prefix":"10.1007","volume":"31","author":[{"given":"Atsushi","family":"Isoda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuri","family":"Miyazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuhei","family":"Kanaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keita","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Mihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirono","family":"Iriuchishima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morio","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morio","family":"Sawamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,1]]},"reference":[{"key":"8021_CR1","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Anderson K (2011) Multiple myeloma. N Engl J Med 364:1046\u20131060","journal-title":"N Engl J Med"},{"key":"8021_CR2","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1002\/cncr.26467","volume":"118","author":"D Van Lammeren-Venema","year":"2012","unstructured":"Van Lammeren-Venema D, Regelink JC, Riphagen II, Zweegman S, Hoekstra OS, Zijlstra JM (2012) 18F-fluoro-deoxyglucose positron emission tomography in assessment of myeloma-related bone disease: a systematic review. Cancer 118:1971\u20131981","journal-title":"Cancer"},{"key":"8021_CR3","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/j.ejca.2007.04.022","volume":"43","author":"K Cocks","year":"2007","unstructured":"Cocks K, Cohen D, Wisl\u00f8ff F, Sezer O, Lee S, Hippe E et al (2007) An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. Eur J Cancer 43:1670\u20131678","journal-title":"Eur J Cancer"},{"key":"8021_CR4","first-page":"1","volume":"4","author":"M Sonmez","year":"2008","unstructured":"Sonmez M, Akagun T, Topbas M, Cobanoglu U, Sonmez B, Yilmaz M et al (2008) Effect of pathologic fractures on survival in multiple myeloma patients\u202f: a case control study. J Exp Clin Cancer Res 4:1\u20134","journal-title":"J Exp Clin Cancer Res"},{"key":"8021_CR5","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1182\/blood-2016-03-707547","volume":"128","author":"G An","year":"2016","unstructured":"An G, Acharya C, Feng X, Wen K, Zhong M, Zhang L et al (2016) Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication. Blood 128:1590\u20131603","journal-title":"Blood"},{"key":"8021_CR6","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1158\/1078-0432.CCR-10-1804","volume":"17","author":"N Raje","year":"2011","unstructured":"Raje N, Roodman GD (2011) Advances in the biology and treatment of bone disease in multiple myeloma. Clin Cancer Res 17:1278\u20131287","journal-title":"Clin Cancer Res"},{"key":"8021_CR7","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/BF03039196","volume":"173","author":"IA Adamietz","year":"1997","unstructured":"Adamietz IA (1997) The efficacy of pamidronate in reducing skeletal associated events in patients with advanced multiple myeloma. Strahlenther Onkol 173:52\u201353","journal-title":"Strahlenther Onkol"},{"key":"8021_CR8","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1200\/JCO.2008.19.2146","volume":"27","author":"K Fizazi","year":"2009","unstructured":"Fizazi K, Lipton A, Mariette X, Body J-J, Rahim Y, Gralow JR et al (2009) Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 27:1564\u20131571","journal-title":"J Clin Oncol"},{"key":"8021_CR9","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1056\/NEJMra070553","volume":"357","author":"MF Holick","year":"2007","unstructured":"Holick MF (2007) Vitamin D deficiency. N Engl J Med 357:266\u2013281","journal-title":"N Engl J Med"},{"key":"8021_CR10","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1007\/s00198-017-3967-6","volume":"28","author":"J Tamaki","year":"2017","unstructured":"Tamaki J, Iki M, Sato Y, Kajita E, Nishino H, Akiba T et al (2017) Total 25-hydroxyvitamin D levels predict fracture risk: results from the 15-year follow-up of the Japanese Population-based Osteoporosis (JPOS) Cohort Study. Osteoporos Int 28:1903\u20131913","journal-title":"Osteoporos Int"},{"key":"8021_CR11","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1152\/physrev.00014.2015","volume":"96","author":"S Christakos","year":"2016","unstructured":"Christakos S, Dhawan P, Verstuyf A, Verlinden L, Carmeliet G (2016) Vitamin D: metabolism, molecular mechanism of action, and pleiotropic effects. Physiol Rev 96:365\u2013408","journal-title":"Physiol Rev"},{"key":"8021_CR12","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1210\/jc.2008-1454","volume":"94","author":"D Bikle","year":"2009","unstructured":"Bikle D (2009) Nonclassic actions of vitamin D. J Clin Endocrinol Metab 94:26\u201334","journal-title":"J Clin Endocrinol Metab"},{"key":"8021_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/nu12072097","volume":"12","author":"N Charoenngam","year":"2020","unstructured":"Charoenngam N, Holick MF (2020) Immunologic effects of vitamin D on human health and disease. Nutrients 12:1\u201328","journal-title":"Nutrients"},{"key":"8021_CR14","doi-asserted-by":"crossref","unstructured":"Oortgiesen BE, Kroes JA, Scholtens P, Hoogland J, Dannenberg - de Keijzer P, Siemes C et al (2022) High prevalence of peripheral neuropathy in multiple myeloma patients and the impact of vitamin D levels, a cross-sectional study. Support Care Cancer 30:271\u20138","DOI":"10.1007\/s00520-021-06414-3"},{"key":"8021_CR15","first-page":"3105","volume":"24","author":"J Wang","year":"2016","unstructured":"Wang J, Udd KA, Vidisheva A, Swift RA, Spektor TM, Bravin E et al (2016) Low serum vitamin D occurs commonly among multiple myeloma patients treated with bortezomib and\/or thalidomide and is associated with severe neuropathy. Support Care Cancer 24:3105\u20133110","journal-title":"Support Care Cancer"},{"key":"8021_CR16","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1210\/jc.2011-0385","volume":"96","author":"MF Holick","year":"2011","unstructured":"Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP et al (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:1911\u20131930","journal-title":"J Clin Endocrinol Metab"},{"key":"8021_CR17","doi-asserted-by":"publisher","first-page":"E213","DOI":"10.1111\/hepr.12972","volume":"48","author":"R Yu","year":"2018","unstructured":"Yu R, Tan D, Ning Q, Niu J, Bai X, Chen S et al (2018) Association of baseline vitamin D level with genetic determinants and virologic response in patients with chronic hepatitis B. Hepatol Res 48:E213\u2013E221","journal-title":"Hepatol Res"},{"key":"8021_CR18","doi-asserted-by":"publisher","first-page":"5769","DOI":"10.1182\/blood.V124.21.5769.5769","volume":"124","author":"N Ravenborg","year":"2014","unstructured":"Ravenborg N, Udd K, Berenson A, Costa F, Berenson JR (2014) Vitamin D levels are frequently below normal in multiple myeloma patients and are infrequently assessed by their treating physicians. Blood 124:5769","journal-title":"Blood"},{"key":"8021_CR19","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blad\u00e9 J et al (2005) International staging system for multiple myeloma. J Clin Oncol 23:3412\u20133420","journal-title":"J Clin Oncol"},{"key":"8021_CR20","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","volume":"36","author":"BG Durie","year":"1975","unstructured":"Durie BG, Salmon SE (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36:842\u201354","journal-title":"Cancer"},{"key":"8021_CR21","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV et al (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15:e538\u2013e548","journal-title":"Lancet Oncol"},{"key":"8021_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1507\/endocrj.EJ16-0548","volume":"64","author":"R Okazaki","year":"2017","unstructured":"Okazaki R, Ozono K, Fukumoto S, Inoue D, Yamauchi M, Minagawa M et al (2017) Assessment criteria for vitamin d deficiency\/insufficiency in Japan \u2014 proposal by an expert panel supported by research program of intractable diseases, ministry of health, labour and welfare, Japan, the Japanese society for bone and mineral research and. Endocr J 64:1\u20136","journal-title":"Endocr J"},{"key":"8021_CR23","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant 48:452\u2013458","journal-title":"Bone Marrow Transplant"},{"key":"8021_CR24","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00198-014-2844-9","volume":"26","author":"N Yoshimura","year":"2015","unstructured":"Yoshimura N, Muraki S, Oka H, Nakamura K, Kawaguchi H, Tanaka S et al (2015) Serum levels of 25-hydroxyvitamin D and the occurrence of musculoskeletal diseases: a 3-year follow-up to the road study. Osteoporos Int 26:151\u2013161","journal-title":"Osteoporos Int"},{"key":"8021_CR25","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/j.1365-2141.2008.07214.x","volume":"142","author":"A Badros","year":"2008","unstructured":"Badros A, Goloubeva O, Terpos E, Milliron T, Baer MR, Streeten E (2008) Prevalence and significance of vitamin D deficiency in multiple myeloma patients. Br J Haematol 142:492\u2013494","journal-title":"Br J Haematol"},{"key":"8021_CR26","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1182\/bloodadvances.2019001411","volume":"4","author":"SV Yellapragada","year":"2020","unstructured":"Yellapragada SV, Fillmore NR, Frolov A, Zhou Y, Dev P, Yameen H et al (2020) Vitamin D deficiency predicts for poor overall survival in white but not African American patients with multiple myeloma. Blood Adv 4:1643\u20131646","journal-title":"Blood Adv"},{"key":"8021_CR27","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/ajh.21412","volume":"84","author":"AC Ng","year":"2009","unstructured":"Ng AC, Kumar SK, Rajkumar SV, Drake MT (2009) Impact of vitamin D deficiency on the clinical presentation and prognosis of patients with newly diagnosed multiple myeloma. Am J Hematol 84:397\u2013400","journal-title":"Am J Hematol"},{"key":"8021_CR28","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1007\/s00520-019-04942-7","volume":"28","author":"K Nath","year":"2020","unstructured":"Nath K, Ganeshalingam V, Ewart B, Heyer E, Watt K, Birchley A et al (2020) A retrospective analysis of the prevalence and clinical outcomes of vitamin D deficiency in myeloma patients in tropical Australia. Support care cancer 28:1249\u20131254","journal-title":"Support care cancer"},{"key":"8021_CR29","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/ajh.21619","volume":"85","author":"T Diamond","year":"2010","unstructured":"Diamond T, Golombick T, Manoharan A (2010) Vitamin D status may effect the skeletal complications of multiple myeloma. Am J Hematol 85:302\u2013303","journal-title":"Am J Hematol"},{"key":"8021_CR30","doi-asserted-by":"publisher","first-page":"505","DOI":"10.3109\/07357907.2015.1081690","volume":"33","author":"B Lauter","year":"2015","unstructured":"Lauter B, Schmidt-Wolf IGH (2015) Prevalence, supplementation, and impact of vitamin D deficiency in multiple myeloma patients. Cancer Invest 33:505\u2013509","journal-title":"Cancer Invest"},{"key":"8021_CR31","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41408-017-0015-x","volume":"7","author":"B Lipe","year":"2017","unstructured":"Lipe B, Kambhampati S, Van Veldhuizen P, Yacoub A, Aljitawi O, Mikhael J (2017) Correlation between markers of bone metabolism and vitamin D levels in patients with monoclonal gammopathy of undetermined significance (MGUS). Blood Cancer J 7:4\u20137","journal-title":"Blood Cancer J"},{"key":"8021_CR32","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/j.1365-2141.2005.05733.x","volume":"131","author":"M Zangari","year":"2005","unstructured":"Zangari M, Esseltine D, Lee CK, Barlogie B, Elice F, Burns MJ et al (2005) Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol 131:71\u201373","journal-title":"Br J Haematol"},{"key":"8021_CR33","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1532\/IJH97.07030","volume":"86","author":"S Ozaki","year":"2007","unstructured":"Ozaki S, Tanaka O, Fujii S, Shigekiyo Y, Miki H, Choraku M et al (2007) Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma. Int J Hematol 86:180\u2013185","journal-title":"Int J Hematol"},{"key":"8021_CR34","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/j.1365-2141.2006.06356.x","volume":"135","author":"E Terpos","year":"2006","unstructured":"Terpos E, Heath DJ, Rahemtulla A, Zervas K, Chantry A, Pouli A et al (2006) Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor- j B ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol 135:688\u2013692","journal-title":"Br J Haematol"},{"key":"8021_CR35","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/ejh.12069","volume":"90","author":"MF Kaiser","year":"2013","unstructured":"Kaiser MF, Heider U, Mieth M, Zang C, von Metzler I, Sezer O (2013) The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of human osteoblast precursors via upregulation of vitamin D receptor signalling. Eur J Haematol 90:263\u2013272","journal-title":"Eur J Haematol"},{"key":"8021_CR36","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1007\/s00774-013-0520-3","volume":"32","author":"S Tanaka","year":"2014","unstructured":"Tanaka S, Kuroda T, Yamazaki Y, Shiraki Y, Yoshimura N, Shiraki M (2014) Serum 25-hydroxyvitamin D below 25 ng\/mL is a risk factor for long bone fracture comparable to bone mineral density in Japanese postmenopausal women. J Bone Miner Metab 32:514\u2013523","journal-title":"J Bone Miner Metab"},{"key":"8021_CR37","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.bone.2012.03.026","volume":"51","author":"P Peris","year":"2012","unstructured":"Peris P, Mart\u00ednez-Ferrer A, Monegal A, Mart\u00ednez de Osaba MJ, Muxi A, Gua\u00f1abens N (2012) 25 hydroxyvitamin D serum levels influence adequate response to bisphosphonate treatment in postmenopausal osteoporosis. Bone 51:54\u20138","journal-title":"Bone"},{"key":"8021_CR38","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1007\/s00198-011-1868-7","volume":"23","author":"AS Carmel","year":"2012","unstructured":"Carmel AS, Shieh A, Bang H, Bockman RS (2012) The 25(OH)D level needed to maintain a favorable bisphosphonate response is \u226533 ng\/ml. Osteoporos Int 23:2479\u20132487","journal-title":"Osteoporos Int"},{"key":"8021_CR39","doi-asserted-by":"publisher","first-page":"5655","DOI":"10.1182\/blood.V128.22.5655.5655","volume":"128","author":"V Rakhee","year":"2016","unstructured":"Rakhee V, Ahlers S, Rodriguez C, Zanetta S, Lamar DDH (2016) Low pre-transplant vitamin D levels predict an inferior survival in patients with multiple myeloma undergoing an autologous stem cell transplant. Blood 128:5655","journal-title":"Blood"},{"key":"8021_CR40","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1002\/hon.2774","volume":"38","author":"F Eicher","year":"2020","unstructured":"Eicher F, Mansouri Taleghani B, Schild C, Bacher U, Pabst T (2020) Reduced survival after autologous stem cell transplantation in myeloma and lymphoma patients with low vitamin D serum levels. Hematol Oncol 38:523\u2013530","journal-title":"Hematol Oncol"},{"key":"8021_CR41","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1046\/j.1365-2141.2000.02046.x","volume":"109","author":"WH Park","year":"2000","unstructured":"Park WH, Seol JG, Kim ES, Hyun JM, Jung CW, Lee CC et al (2000) Induction of apoptosis by vitamin D3 analogue EB1089 in NCI-H929 myeloma cells via activation of caspase 3 and p38 MAP kinase. Br J Haematol 109:576\u2013583","journal-title":"Br J Haematol"},{"key":"8021_CR42","doi-asserted-by":"publisher","first-page":"10","DOI":"10.18632\/oncotarget.26531","volume":"10","author":"C Flamann","year":"2019","unstructured":"Flamann C, Busch L, Mackensen A, Bruns H (2019) Combination of lenalidomide and Vitamin D enhances MOR202-mediated cytotoxicity of macrophages: It takes three to tango. Oncotarget 10:10\u201312","journal-title":"Oncotarget"},{"key":"8021_CR43","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1159\/000080693","volume":"50","author":"F Ozdemir","year":"2004","unstructured":"Ozdemir F, Esen N, Ovali E, Tekelioglu Y, Yilmaz M, Aydin F et al (2004) Effects of dexamethasone, all-trans retinoic acid, vitamin D(3) and interferon-alpha on FO myeloma cells. Chemotherapy 50:190\u2013193","journal-title":"Chemotherapy"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-08021-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-023-08021-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-08021-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T07:03:09Z","timestamp":1718694189000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-023-08021-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":43,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["8021"],"URL":"https:\/\/doi.org\/10.1007\/s00520-023-08021-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1621537\/v1","asserted-by":"object"}]},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"4 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. All study protocols were reviewed and approved by the ethics review board at Nishigunma Hospital (approval nos. 15-11-04, 16-01-03) and the study was registered to the University Hospital Medical Information Network Clinical Trials Registry (UMIN000042804).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants provided written informed consent prior to participation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"N\/A.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"M. Matsumoto received an honorarium from Janssen Pharmaceutical and Sanofi K.K.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"547"}}